MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
Published May 18, 2022 · Recall initiated: May 2, 2022
Summary
FDA records drug Class II recall D-0855-2022, published May 18, 2022 and initiated May 2, 2022. Recalling firm: Amgen, Inc.; Status: Terminated; Reported quantity: 15,823; Lot: Lots: 1142258, 1143196, Exp. 09/24. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Defective container: loose crimp defect, potential loss of container integrity.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Amgen, Inc.
- Distributor
- Nationwide in the USA, Egypt and Lithuania.
- Lot
- Lots: 1142258, 1143196, Exp. 09/24
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACorlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made InJuly 1, 2026
- FDACorlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tabletJuly 1, 2026
- FDASensipar (cinacalcet) Tablets, 30mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive,July 1, 2026
- FDASensipar (cinacalcet) Tablets, 90mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive,July 1, 2026
- FDAXanax XR (alprazolam) extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by Pharmacia &May 18, 2022
- FDASyrSpend SF Suspending Base, Cherry Flavored, packaged in a) 500mL bottles (NDC 51552-1123-5) and b) 4LMay 18, 2022
Questions about this recall
Was MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01 recalled?
Yes. FDA published recall D-0855-2022 on May 18, 2022. Reported hazard: Defective container: loose crimp defect, potential loss of container integrity.
What should I do if I have this product?
Voluntary: Firm initiated · Letter